Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE)

robot
Abstract generation in progress

Xenon Pharmaceuticals (NASDAQ:XENE) experienced unusually high options trading on Wednesday, with put options increasing by 2,362%, indicating potential bearish sentiment or hedging. Despite recent insider selling totaling $19.6 million over 90 days, analysts broadly rate the stock as a “Buy” with a consensus price target of $71.88. The company, a clinical-stage biopharmaceutical firm, focuses on neurological and pain disorders by targeting ion channels.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin